Pancreatic Cancer Research

ResearcherTokyo Medical UniversityNo recent work listed

Xiaofang Che

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9087-1007; OpenAlex author ID A5088595151. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
13
Papers, trials and grants by year

2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 8

  1. microRNA-569 inhibits tumor metastasis in pancreatic cancer by directly targeting NUSAP1. Co-author DOI 10.18632/aging.204035↗
  2. PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells. Co-author DOI 10.1007/s12032-020-01372-y↗
  3. DNMT3a promotes proliferation by activating the STAT3 signaling pathway and depressing apoptosis in pancreatic cancer. Co-author DOI 10.2147/cmar.s201610↗
  4. MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-018-4526-z↗
  5. DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells. Last author DOI 10.3892/mmr.2017.7923↗
  6. Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.18714↗
  7. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.11001↗
  8. Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. Co-author DOI 10.3892/ijo.2015.3237↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ce Li · 6 shared papers, 2016–2022 · strength 0.59
  2. Xiujuan Qu · 5 shared papers, 2016–2022 · strength 0.47
  3. Na Song · 3 shared papers, 2018–2020 · strength 0.30
  4. Wei Jing · 3 shared papers, 2018–2020 · strength 0.30
  5. Xianghong Yang · 3 shared papers, 2016–2018 · strength 0.22
  6. Xiaohui Guo · 1 shared paper, 2022 · strength 0.19
  7. Yunpeng Liu · 2 shared papers, 2018–2020 · strength 0.18
  8. Qian Dong · 2 shared papers, 2016–2017 · strength 0.12
  9. Xiang-Hong Yang · 1 shared paper, 2019 · strength 0.10
  10. Zhi Li · 1 shared paper, 2017 · strength 0.06
  11. Shuntaro Mukai · 1 shared paper, 2016 · strength 0.05
  12. Keisuke Miyazawa · 1 shared paper, 2016 · strength 0.05
  13. Takao Itoi · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.